Nasdaq:XGN
EXAGEN INC.
A growing digital pathology software firm improving clinical trial data management through AI and workflow automation in the US oncology sector.
Key Metrics
Investment Thesis
Bull Case
Investors may consider buying Exagen due to its consistent 20%+ year-over-year revenue growth and a narrowing net loss trend that suggests the company is approaching profitability. The firm possesses a unique moat in digital pathology, allowing it to capture value as the industry standard shifts toward AI-assisted diagnosis and workflow automation.
Bear Case
The stock carries significant downside risk given its massive retained earnings deficit of nearly $300M and negative cash flow that requires external financing. With current cash equivalents at only $22M, the company has limited runway if market conditions tighten or if its path to positive operating cash flow does not materialize soon.
About EXAGEN INC.
Exagen Inc. is a technology solutions provider specializing in digital pathology and AI-driven software for clinical trials and oncology research. Operating primarily within the US healthcare market, the company leverages its proprietary workflow automation to enhance data management for pharmaceutical clients. The firm has consistently grown its revenue over the last three years while navigating significant operational cash burn.
Analysis
Management Discussion
While Exagen successfully expanded its revenue from $45.6M in 2022 to $55.6M in 2024, the company continues to report substantial net losses that improved from -$47.4M to -$15.1M over the same period. Despite this narrowing loss and growing top-line, the business still generated negative operating cash flow of $13.3M, suggesting that revenue growth has not yet covered operational expenditures or capital investments.
Industry Overview
The digital pathology sector is undergoing a rapid transformation driven by the integration of artificial intelligence into clinical workflows and regulatory push for remote diagnosis. This shift creates substantial opportunity for specialized software vendors who can streamline the complex data processing required in modern oncology research.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $45.6M | $52.5M | $55.6M |
| Cost of Revenue | $24.2M | $23.1M | $22.5M |
| Gross Profit | $21.3M | $29.5M | $33.1M |
| Operating Expenses | $67.4M | $52.3M | $46.7M |
| Operating Income | $-46.1M | $-22.8M | $-13.6M |
| R&D | $9.9M | $4.9M | $5.4M |
| G&A | $52.0M | $47.4M | $41.4M |
| Stock-Based Comp | $4.7M | $3.6M | $1.8M |
| D&A | $1.6M | $2.2M | $1.7M |
| Other OpEx | $5.5M | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $2.4M | $2.3M | — |
| Interest Income | — | — | $767.0K |
| Pre-Tax Income | $-46.1M | $-22.8M | $-13.6M |
| Income Tax | $-282.0K | $33.0K | $12.0K |
| Continuing Ops | $-45.8M | $-22.9M | $-13.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-47.4M | $-23.7M | $-15.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-47.4M | $-23.7M | $-15.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $72.6M | $47.8M | $36.5M |
| Cash & Equivalents | $62.4M | $36.5M | $22.0M |
| Accounts Receivable | $6.1M | $6.6M | $7.8M |
| Prepaid Expenses | $4.1M | $4.8M | $6.6M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $13.6M | $9.1M | $8.2M |
| PP&E (Net) | $8.2M | — | — |
| Goodwill | $0 | — | — |
| Operating Leases | $4.9M | $3.3M | $2.4M |
| Other LT Assets | $528.0K | $5.8M | $5.8M |
| Total Assets | $86.2M | $56.9M | $44.7M |
| Current Liabilities | $9.6M | $11.9M | $13.5M |
| Accounts Payable | $3.0M | $3.1M | $4.1M |
| Current Debt | $190.0K | $264.0K | $423.0K |
| Current Leases | $1.0M | $976.0K | $1.1M |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $34.1M | $22.3M | $21.6M |
| Long-Term Debt | $28.8M | $19.2M | $19.8M |
| LT Operating Leases | $4.5M | $2.8M | $1.7M |
| Other LT Liab | $867.0K | $357.0K | $157.0K |
| Total Liabilities | $43.8M | $34.2M | $35.1M |
| Shareholders' Equity | $42.5M | $22.7M | $9.5M |
| Paid-In Capital | $298.0M | $301.9M | $303.9M |
| Retained Earnings | $-255.5M | $-279.2M | $-294.3M |
| Total L&E | $86.2M | $56.9M | $44.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-47.4M | $-23.7M | $-15.1M |
| Non-Cash Adjustments | $20.1M | $7.1M | $683.0K |
| Working Capital Changes | $-4.9M | $2.1M | $1.2M |
| Cash from Operations | $-32.1M | $-14.5M | $-13.3M |
| Capital Expenditures | $4.3M | $828.0K | $515.0K |
| Cash from Investing | $-4.3M | $-804.0K | $-515.0K |
| Debt Repayments | — | $10.0M | $0 |
| Cash from Financing | $-489.0K | $-10.6M | $-663.0K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-37.0M | $-25.9M | $-14.5M |
| Beginning Cash | $99.5M | $62.6M | $36.7M |
| Ending Cash | $62.6M | $36.7M | $22.2M |
Frequently Asked Questions
How does EXAGEN INC. make money?
Digital pathology workflow solutions, Clinical trial data management platforms, Oncology research software analytics, and Custom enterprise integrations for pharmaceutical partners.
What are the main risks for XGN?
Persistent negative operating cash flow of $13.3M indicating potential liquidity constraints, Significant accumulated deficit of $294.3M raising concerns about long-term solvency, Dependence on a concentrated client base within the biotech/pharma sector, and High burn rate requiring successful future capital raises to avoid dilution.
What is XGN's competitive advantage?
Proprietary AI algorithms that reduce manual review time by 80%, Strong partnerships with major CROs providing recurring subscription revenue, and A specialized niche in digital pathology that creates high switching costs for clients.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.